Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SJ in connection with agreement governing restoration of SJ 2000 trains
Mandate

Vinge advises SJ in connection with agreement governing restoration of SJ 2000 trains

January 16, 2014

SJ is making one of the largest commitments in the company’s 150-year history by investing in a comprehensive renewal and restoration programme for its fleet of SJ 2000 trains. SJ has entered into an agreement with ABB concerning the initial technical restoration of the entire fleet of SJ 2000 trains (previously X 2000). This phase of the renovation will cost approximately SEK 1.4 billion. The first newly-renovated SJ 2000 train will be put into operation in 2016, although the renewal and restoration programme will continue until 2019. The renovation is anticipated to reduce energy consumption by approximately 10 per cent.

Vinge’s team consisted of, among others, partners Eva Fredrikson and Björn Gustavsson and associate Mikael Satama Grönberg.   

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026